RU2765286C2 - Фармацевтические агенты, композиции и способы, относящиеся к ним - Google Patents

Фармацевтические агенты, композиции и способы, относящиеся к ним Download PDF

Info

Publication number
RU2765286C2
RU2765286C2 RU2019134865A RU2019134865A RU2765286C2 RU 2765286 C2 RU2765286 C2 RU 2765286C2 RU 2019134865 A RU2019134865 A RU 2019134865A RU 2019134865 A RU2019134865 A RU 2019134865A RU 2765286 C2 RU2765286 C2 RU 2765286C2
Authority
RU
Russia
Prior art keywords
compound
insulin
glucose
cells
mice
Prior art date
Application number
RU2019134865A
Other languages
English (en)
Russian (ru)
Other versions
RU2019134865A3 (https=
RU2019134865A (ru
Inventor
Цзы-Цзянь ЛАНЬ
Ронан Пауэр
Александрос ЯННИКУРИС
Тирупати Редди ЙЕРРАМРЕДДИ
Original Assignee
Оллтек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оллтек, Инк. filed Critical Оллтек, Инк.
Publication of RU2019134865A publication Critical patent/RU2019134865A/ru
Publication of RU2019134865A3 publication Critical patent/RU2019134865A3/ru
Application granted granted Critical
Publication of RU2765286C2 publication Critical patent/RU2765286C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
RU2019134865A 2017-05-19 2018-05-01 Фармацевтические агенты, композиции и способы, относящиеся к ним RU2765286C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762508730P 2017-05-19 2017-05-19
US62/508,730 2017-05-19
PCT/US2018/030371 WO2018212980A1 (en) 2017-05-19 2018-05-01 Pharmaceutical agents, compositions, and methods relating thereto

Publications (3)

Publication Number Publication Date
RU2019134865A RU2019134865A (ru) 2021-06-21
RU2019134865A3 RU2019134865A3 (https=) 2021-06-30
RU2765286C2 true RU2765286C2 (ru) 2022-01-28

Family

ID=64274560

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019134865A RU2765286C2 (ru) 2017-05-19 2018-05-01 Фармацевтические агенты, композиции и способы, относящиеся к ним

Country Status (10)

Country Link
US (2) US11014954B2 (https=)
EP (1) EP3624809A4 (https=)
JP (1) JP7224303B2 (https=)
CN (2) CN110545822A (https=)
AU (1) AU2018269403B2 (https=)
CA (1) CA3061893A1 (https=)
RU (1) RU2765286C2 (https=)
SA (1) SA519410561B1 (https=)
SG (1) SG11201909932YA (https=)
WO (1) WO2018212980A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018269403B2 (en) 2017-05-19 2025-03-27 Alltech, Inc. Pharmaceutical agents, compositions, and methods relating thereto

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2298557C2 (ru) * 2001-08-08 2007-05-10 Си Ви Терапьютикс, Инк. Агонисты а3 рецепторов аденозина
EP3144001A1 (en) * 2015-09-15 2017-03-22 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
WO2017048253A1 (en) * 2014-03-14 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002077002A2 (en) * 2001-03-22 2002-10-03 Research Foundation Of The City University Of New York Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids
EP1652519A1 (en) 2004-10-28 2006-05-03 Tamie Nasu Seleniferous composition for producing antioxidase in vivo
US20060198906A1 (en) 2005-03-07 2006-09-07 Sami Labs Limited Compositions and Method to Increase Serum Levels of HDL cholesterol and Lower the Risk of Cardiovascular Disease
US20070077238A1 (en) 2005-10-04 2007-04-05 Teo Alex Y Production of organic and inorganic selenium compounds by lactic acid bacteria
WO2007047401A2 (en) 2005-10-13 2007-04-26 Cv Therapeutics, Inc. A1 adenosine receptor agonists
WO2009032057A2 (en) 2007-08-29 2009-03-12 Adam Lubin Method for the selective therapy of disease
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
US9833486B2 (en) 2013-03-15 2017-12-05 Alltech, Inc. Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
US20160090397A1 (en) 2014-09-30 2016-03-31 Northeastern University Se-Adenosyl-L-Selenohomocysteine Selenoxide As A Modulator Of Methyltransferase And Other Activities
AU2018269403B2 (en) 2017-05-19 2025-03-27 Alltech, Inc. Pharmaceutical agents, compositions, and methods relating thereto

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2298557C2 (ru) * 2001-08-08 2007-05-10 Си Ви Терапьютикс, Инк. Агонисты а3 рецепторов аденозина
WO2017048253A1 (en) * 2014-03-14 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
EP3144001A1 (en) * 2015-09-15 2017-03-22 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof

Also Published As

Publication number Publication date
SG11201909932YA (en) 2019-11-28
JP7224303B2 (ja) 2023-02-17
BR112019022918A2 (pt) 2020-05-26
JP2020520904A (ja) 2020-07-16
US20200123191A1 (en) 2020-04-23
CA3061893A1 (en) 2018-11-22
US20210238216A1 (en) 2021-08-05
NZ758538A (en) 2025-08-29
WO2018212980A1 (en) 2018-11-22
AU2018269403B2 (en) 2025-03-27
US11613552B2 (en) 2023-03-28
RU2019134865A3 (https=) 2021-06-30
US11014954B2 (en) 2021-05-25
CN110545822A (zh) 2019-12-06
SA519410561B1 (ar) 2024-03-06
CN120647702A (zh) 2025-09-16
EP3624809A1 (en) 2020-03-25
RU2019134865A (ru) 2021-06-21
AU2018269403A1 (en) 2019-11-14
EP3624809A4 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
US9642874B2 (en) Compositions of selenoorganic compounds and methods of use thereof
US6521645B2 (en) Methods for the treatment and prevention of urinary stone disease
US11247970B2 (en) Selective inhibition of gluconeogenic activity
RU2765286C2 (ru) Фармацевтические агенты, композиции и способы, относящиеся к ним
US7674784B2 (en) Drug and food or drink for improving hyperglycemia
WO2024102114A1 (en) Methods and compositions for treating wolfram syndrome
JP2003519660A (ja) 耐糖能に影響を与える薬剤を調製するための、環状エーテルの使用
Kim et al. Enhancing effect of indirubin derivatives on 1, 25-dihydroxyvitamin D3-and all-trans retinoic acid-induced differentiation of HL-60 leukemia cells
HK40017181A (en) Pharmaceutical agents, compositions, and methods relating thereto
US20050119197A1 (en) Naadp analogues for modulating t-cell activity
BR112019022918B1 (pt) Compostos farmacêuticos contendo selênio para modulação do metabolismo da glicose, composições farmacêuticas e seus usos
EP3144001B1 (en) Compositions of selenoorganic compounds and methods of use thereof
CN110799518B (zh) 钴胺素衍生物及其用于治疗因缺乏维生素b12供应引起的疾病的用途
US20250009692A1 (en) Micronutrient composition to prevent and reverse protein glycation during oxidative stress in human
WO2007066615A1 (ja) 核内オーファン受容体の新規活性化剤及びその用途
RU2316327C1 (ru) Ксимедон в качестве индуктора активности микросомальных оксидаз печени человека
Li et al. Antidiabetic compounds 8a, 8b, 8k, and 9h enhance insulin secretion: Activity and mechanism
RU2768171C2 (ru) Применение производного роданина 3-(2 -фенилэтил)-2-тиоксо-1,3 тиазолидин-4-она для коррекции нарушений обмена веществ
HK40067960A (en) Therapeutic or prophylactic method for diabetes using combination medicine
JP2021024826A (ja) 糖化産物生成抑制剤及び医薬組成物
WO2011120576A1 (en) Antidiabetic enolic glucoside of phenylpyruvic acid